Hologic, Inc. $HOLX Shares Sold by Candriam S.C.A.

Candriam S.C.A. cut its position in Hologic, Inc. (NASDAQ:HOLX) by 7.2% in the second quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 399,277 shares of the medical equipment provider’s stock after selling 30,864 shares during the quarter. Candriam S.C.A.’s holdings in Hologic were worth $26,018,000 at the end of the most recent quarter.

Other institutional investors also recently added to or reduced their stakes in the company. Chung Wu Investment Group LLC purchased a new stake in Hologic in the second quarter valued at approximately $26,000. Caitong International Asset Management Co. Ltd increased its holdings in shares of Hologic by 193.6% in the 2nd quarter. Caitong International Asset Management Co. Ltd now owns 414 shares of the medical equipment provider’s stock valued at $27,000 after acquiring an additional 273 shares during the period. Zions Bancorporation National Association UT purchased a new stake in Hologic in the 1st quarter valued at $34,000. Cromwell Holdings LLC boosted its stake in Hologic by 307.0% during the 2nd quarter. Cromwell Holdings LLC now owns 578 shares of the medical equipment provider’s stock worth $38,000 after purchasing an additional 436 shares during the period. Finally, Allworth Financial LP grew its position in Hologic by 46.0% during the 1st quarter. Allworth Financial LP now owns 686 shares of the medical equipment provider’s stock worth $40,000 after purchasing an additional 216 shares during the last quarter. Institutional investors and hedge funds own 94.73% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently commented on HOLX shares. BTIG Research reaffirmed a “neutral” rating on shares of Hologic in a report on Tuesday, October 21st. Raymond James Financial cut Hologic from a “moderate buy” rating to a “hold” rating in a research report on Wednesday, October 22nd. Leerink Partners upped their price target on Hologic from $70.00 to $78.00 and gave the stock a “market perform” rating in a research note on Tuesday, October 21st. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Hologic in a report on Friday, October 31st. Finally, UBS Group boosted their price objective on shares of Hologic from $65.00 to $70.00 and gave the company a “neutral” rating in a research note on Thursday, July 31st. One equities research analyst has rated the stock with a Strong Buy rating, five have given a Buy rating and thirteen have issued a Hold rating to the company. According to data from MarketBeat, the stock has a consensus rating of “Hold” and an average target price of $79.77.

Insider Activity

In other Hologic news, Director Christiana Stamoulis sold 7,402 shares of the company’s stock in a transaction dated Monday, October 20th. The shares were sold at an average price of $73.07, for a total transaction of $540,864.14. Following the transaction, the director directly owned 47,336 shares in the company, valued at approximately $3,458,841.52. This represents a 13.52% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, CEO Stephen P. Macmillan sold 138,358 shares of Hologic stock in a transaction that occurred on Monday, September 22nd. The shares were sold at an average price of $66.97, for a total transaction of $9,265,835.26. Following the sale, the chief executive officer owned 1,234,624 shares of the company’s stock, valued at approximately $82,682,769.28. The trade was a 10.08% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Corporate insiders own 1.88% of the company’s stock.

Hologic Trading Down 0.4%

NASDAQ:HOLX opened at $74.26 on Friday. Hologic, Inc. has a 1 year low of $51.90 and a 1 year high of $80.31. The company has a debt-to-equity ratio of 0.52, a quick ratio of 2.81 and a current ratio of 3.55. The stock has a fifty day moving average price of $69.62 and a two-hundred day moving average price of $65.57. The stock has a market capitalization of $16.52 billion, a price-to-earnings ratio of 30.81, a PEG ratio of 2.54 and a beta of 0.65.

Hologic (NASDAQ:HOLX) last issued its earnings results on Monday, November 3rd. The medical equipment provider reported $1.13 EPS for the quarter, topping the consensus estimate of $1.10 by $0.03. The company had revenue of $1.05 billion for the quarter, compared to analyst estimates of $1.03 billion. Hologic had a net margin of 13.79% and a return on equity of 19.69%. The business’s revenue was up 6.2% on a year-over-year basis. During the same period in the previous year, the firm earned $1.01 EPS. As a group, sell-side analysts anticipate that Hologic, Inc. will post 4.28 earnings per share for the current fiscal year.

About Hologic

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.